PCSK9 Inhibition: From Current Advances to Evolving Future
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secretory serine protease synthesized primarily by the liver. It mainly promotes the degradation of low-density lipoprotein receptor (LDL-R) by binding LDL-R, reducing low-density lipoprotein cholesterol (LDL-C) clearance. In addition to reg...
Main Authors: | Chunping Liu, Jing Chen, Huiqi Chen, Tong Zhang, Dongyue He, Qiyuan Luo, Jiaxin Chi, Zebin Hong, Yizhong Liao, Shihui Zhang, Qizhe Wu, Huan Cen, Guangzhong Chen, Jinxin Li, Lei Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-09-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/11/19/2972 |
Similar Items
-
Insight into the Evolving Role of PCSK9
by: Mateusz Maligłówka, et al.
Published: (2022-03-01) -
PCSK9: BIOLOGICAL ACTIVITY REGULATION AND CONNECTION WITH LIPID AND CARBOHYDRATE METABOLISM
by: A O Averkova
Published: (2017-09-01) -
The association between circulatory, local pancreatic PCSK9 and type 2 diabetes mellitus: The effects of antidiabetic drugs on PCSK9
by: Fengyuan Lu, et al.
Published: (2023-09-01) -
The effect of PCSK9 immunization on the hepatic level of microRNAs associated with PCSK9/LDLR pathway.
by: Sarina Ataei, et al.
Published: (2023-01-01) -
PCSK9 Associated Promoter Methylation Status
in Patients with Hyperlipidemia
by: Samaneh Bahrami, et al.
Published: (2021-08-01)